Aeglea Bio Therapeutics Inc (AGLE) Stock
AGLE is no longer traded. Aeglea Bio Therapeutics was delisted from the Nasdaq in January 2024.
Prices on this page are historical; the last trade was January 30, 2024 at $27.60.
Aeglea Bio Therapeutics stock price history
AGLE final trading statistics
- Final close
- $27.60
- Final trading day
- Jan 30, 2024
- Market cap at delisting
- $48.63M
- Shares outstanding
- 4.05M
- Final 52-week range
- $0.11 – $28.66
- Avg. volume (final 3 mo.)
- 166,139
- All-time high (split-adj.)
- $299.75 · Apr 2016
- All-time low (split-adj.)
- $2.66 · Jun 2023
- Return since IPO
- -88.7%
- Beta
- 2.57
- Book value / share
- -$60.61
- Price / book
- -0.46
Aeglea Bio Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $1.05M | -$294.4M | — |
| FY2022 | $2.33M | -$83.8M | -$1.01 |
| FY2021 | $18.74M | -$65.8M | -$1.00 |
| FY2020 | $21.8K | -$80.3M | -$1.61 |
| FY2019 | $0.00 | -$75.7M | -$2.45 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea Bio Therapeutics stock FAQ
What happened to Aeglea Bio Therapeutics stock?
Aeglea Bio Therapeutics stock was delisted from the Nasdaq. Its final close was $27.60 on January 30, 2024.
Is AGLE stock still trading?
No. AGLE was delisted from the Nasdaq in January 2024 and no longer trades on a U.S. exchange.
What was the last price of AGLE stock?
AGLE closed at $27.60 on its final trading day, January 30, 2024, for a market value of about $48.63M.
What were Aeglea Bio Therapeutics's revenue and earnings in its last full fiscal year?
Aeglea Bio Therapeutics reported revenue of $1.05M and net income of -$294.4M in fiscal 2023, its last full year as a public company.
When did Aeglea Bio Therapeutics go public?
Aeglea Bio Therapeutics Inc stock began trading on April 7, 2016.